Products

Product Description

MALT1 Split CISH Probe is designed for the qualitative detection of human MALT1 gene at 18q21.32 in formalin-fixed, paraffin-embedded specimens by chromogenic in situ hybridization (CISH).

Reactivity

Human

Recommend Usage

The product is ready-to-use. No reconstitution, mixing, or dilution is required. Bring probe to room temperature (18-25°C) and mix briefly before use.

Supplied Product

Reagent Provided:

1. Digoxigenin-labeled polynucleotides targeting sequences mapping in 18q21.31-q21.32* (chr18:56,021,766-56,202,885) proximal to the MALT1 breakpoint region
2. Dinitrophenyl-labeled polynucleotides targeting sequences mapping in 18q21.32* (chr18:56,557,814-56,724,408) distal to the MALT1 breakpoint region
3. Formamide based hybridization buffer

*according to Human Genome Assembly GRCh37/hg19

Probe Position

Regulatory Status

For research use only (RUO)

Storage Instruction

Store at 2-8°C in an upright position. Return to storage conditions immediately after use.

Note

The probe is intended to be used in combination with the CISH Implementation Kit 2 (Catalog #: KA5366), which provides necessary reagents for specimen pretreatment and post-hybridization processing.

Hybridization signals of digoxigenin-labeled polynucleotides appear dark green distinct dot-shaped (proximal to the MALT1 breakpoint region), and dinitrophenyl-labeled polynucleotides appear bright red distinct dot-shaped (distal to the MALT1 breakpoint region).
Normal situation: In interphases of normal cells or cells without a translocation involving the MALT1 gene region, two red/green fusion signals appear.
Aberrant situation: One MALT1 gene region affected by a translocation is indicated by one separate green signal and one separate red signal. Other signal distribution may be observed in some abnormal samples which might result in a different signal pattern than described above, indicating variant rearrangements.
Unexpected signal patterns should be further investigated.

Interpretation of Result

Self-Attestation

Abnova self-attests to comply with the U.S. Framework for Nucleic Acid Synthesis Screening